7,580.07

-140.32

-1.82%

51,770.31

-572.25

-1.09%

25,437.00

-747.73

-2.86%

2,811.84

-47.37

-1.66%

4.9290

-0.0600

-1.20%

19.42

+2.22

+12.91%

3,898.90

-132.50

-3.29%

77,643.56

+632.34

+0.82%

Crude Oil Dec 26

104.12

+2.12

+2.08%

US Private Equity

10,850.63

-82.20

-0.75%

Paris - Delayed Quote EUR

Ipsen S.A. (IPN.PA)

157.60 +1.80 (+1.16%)

At close: October 30 at 5:35:12 PM GMT+1

Loading Chart for IPN.PA

Chart Range Bar

Interval:

In partnership with ChartIQ

Charles River Laboratories (CRL) Expands Virtual Control Group Use In Toxicology Studies

Charles River Laboratories (CRL) Expands Virtual Control Group Use In Toxicology Studies

Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance

Ipsen delivers outstanding sales growth in the first nine months of 2026 and further upgrades its full-year guidance

Ipsen (ENXTPA:IPN) Could Be 11% Undervalued Following Board Changes

Ipsen (ENXTPA:IPN) Could Be 11% Undervalued Following Board Changes

AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod

AMRX Stock Advances As Generic To Ipsen’s Hormone Shot Gets FDA Nod

Ipsen appoints Mariette Finet to its Board of Directors

Ipsen appoints Mariette Finet to its Board of Directors

Ipsen (ENXTPA:IPN) Stock Could Be 45% Below Fair Value Despite Kartos Deal

Ipsen (ENXTPA:IPN) Stock Could Be 45% Below Fair Value Despite Kartos Deal

Ipsen SA (IPSEY) (H1 2026) Earnings Call Highlights: Record Sales and Margin Growth Amid ...

Ipsen SA (IPSEY) (H1 2026) Earnings Call Highlights: Record Sales and Margin Growth Amid ...

Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance

Ipsen delivers excellent H1 2026 results and upgrades its full-year guidance

Ipsen nominates Catherine Bradley to its Board of Directors as independent Director

Ipsen nominates Catherine Bradley to its Board of Directors as independent Director

Ipsen’s Bylvay fails in Phase III biliary atresia study

Ipsen’s Bylvay fails in Phase III biliary atresia study

Ipsen provides update on Phase III BOLD trial in biliary atresia

Ipsen provides update on Phase III BOLD trial in biliary atresia

Mobilize your Website

View Site in Mobile | Classic

Share by: